Emerging markets : 16.3% growth, with Thailand, Mexico and Brazil named as key drivers; India, domestic China and Japan were cited as "white spaces" for expansion. Beiersdorf highlighted Derma as its standout performer. Net sales in the segment reached a record EUR 1.5 billion , approaching 20% of consumer net sales, supported by market share gains even as the broader market grew at low single-digit rates. In the fourth quarter, Derma grew nearly 10% despite a tough comparison versus the prior year's Epicel ...

Core Insights - Investing in healthcare companies can provide both financial returns and ensure these companies are well-funded for future needs [1][2] - The rising demand for healthcare services, driven by increasing household wealth, is likely to lead to higher prices in the sector [3] - Many healthcare companies offer attractive dividends, making them appealing as income-producing assets [4] Company Highlights - GlaxoSmithKline (GSK) has evolved from a specialist in gastrointestinal ailments to one of the top 10 vaccine manufacturers globally, also focusing on drug-resistant superbugs [5] - GSK's spin-off of its Haleon consumer healthcare business allows shareholders to benefit from both segments, with Haleon focusing on oral healthcare and over-the-counter products [6] - Smith & Nephew has a strong presence in consumer healthcare, particularly in orthopaedics, which is expected to grow due to an aging population [7] - Abbott Laboratories offers a diverse range of products, including infant formula and diabetes management solutions, catering to various age groups [8] - Haw Par, known for its Tiger Balm brand, and Reckitt, with products like Nurofen, are also significant players in the consumer healthcare market [9] Market Trends - DFI Retail's shift from low-margin food retailing to focus on 7-Eleven and Guardian pharmacies highlights the higher revenue potential in regulated pharmacy businesses compared to supermarkets [10] - IHH Healthcare operates a large network of upscale hospitals, generating stable revenue, although cash flow can be inconsistent [12] - Parkway Life Real Estate Investment Trust, a major healthcare landlord in Asia, provides a reliable income source by managing hospitals and nursing homes [13] - Health insurance companies, such as AIA and Prudential, play a crucial role in risk management and can invest premiums to generate returns before claims are paid out [14][15] Industry Outlook - The healthcare industry is continuously evolving, with companies needing to adapt to changing consumer demands to remain relevant [15] - Many established healthcare companies have a long history of producing valued products, suggesting they are likely to endure for many more years [16] - A healthcare REIT has secured rental escalations until around 2042, indicating strong income visibility, which is rare in today's market [17]

Financial Data and Key Metrics Changes - For Q3 2025, organic net sales declined by 4.4%, impacted by a 1.6% decline from the global OTC business and a 2.8% decline from businesses under review [11][12] - Year-to-date, organic net sales decreased by 1.7%, primarily driven by a 0.8% impact from businesses under review and a 0.5% impact from the absence of last year's Opill launch stocking benefits [12][24] - Q3 EPS was $0.80, down one cent from the prior year, while year-to-date EPS grew 21% to $1.97 [11][21] Business Line Data and Key Metrics Changes - In the US OTC market, Perrigo gained volume share of 90 basis points across nearly every category, particularly in smoking cessation, allergy, and women's health [6][13] - The CSCI segment saw a 5.3% decline in organic net sales for Q3, primarily due to soft OTC category consumption trends, while year-to-date organic net sales grew by 0.7% [19][20] - The infant formula business experienced a 3.8% decline in Q3, with share recovery taking longer than expected [14][20] Market Data and Key Metrics Changes - US OTC volume consumption declined by 3.2%, while European OTC grew by only 0.6%, falling short of original assumptions [13][24] - The overall market consumption trends have been softer than anticipated, impacting Perrigo's net sales outlook by an estimated $150-$170 million [13][24] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, which has guided its actions and priorities [8][16] - A strategic review of the infant formula business is underway, with the aim to optimize its long-term role within the Perrigo portfolio [14][47] - The sale of the dermocosmetics business is on track to close in Q1 2026, with proceeds aimed at reducing leverage [23][47] Management's Comments on Operating Environment and Future Outlook - Management noted that the current consumption trends are dynamic and unpredictable, with expectations for stabilization in 2026 [41][46] - The company remains committed to deleveraging and sustaining dividends while focusing on high-potential OTC portfolio growth [15][47] - Management expressed confidence in Perrigo's ability to capture durable demand for consumer health solutions despite current challenges [17][46] Other Important Information - The company has achieved $163 million in gross annual savings from Project Energize, exceeding initial expectations [9][18] - Operating cash flow for Q3 was $52 million, with year-to-date cash flow at $63 million [22][23] Q&A Session Summary Question: Follow-up on infant formula share and expectations - Management acknowledged that while store brand share is growing, it is at a slower pace than anticipated due to competitive pressures and market dynamics [28][29] Question: Insights on OTC and infant formula consumption changes - Management noted that OTC consumption has been volatile, with a significant decline observed in Q3 compared to previous quarters [33][34] Question: Plans for reinvestment given current market conditions - Management indicated that while priorities remain on deleveraging and maintaining dividends, there may be opportunities to increase spending in high-performing areas [38][39] Question: Current share of infant formula and future growth expectations - Management reported an approximate 16% share in infant formula, with expectations to grow to 18-20% over the next 12 months [40][41] Question: Clarification on gross margin pressure - Management confirmed that the gross margin pressure was primarily due to sales deleverage and product mix, not input costs [42][43]